Solid Biosciences (SLDB) Accumulated Expenses (2017 - 2026)
Quarterly results put Accumulated Expenses at $19.2 million for Q1 2026, up 31.6% from a year ago — trailing twelve months through Mar 2026 was $19.2 million (up 31.6% YoY), and the annual figure for FY2025 was $18.9 million, down 4.57%.
Solid Biosciences has reported Accumulated Expenses over the past 10 years, most recently at $19.2 million for Q1 2026.
- Accumulated Expenses reached $19.2 million in Q1 2026 per SLDB's latest filing, up from $18.9 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $19.9 million in Q4 2024 and bottomed at $9.4 million in Q1 2022.
- Median Accumulated Expenses over the past 5 years was $13.2 million (2024), compared with a mean of $14.0 million.
- The largest annual shift saw Accumulated Expenses surged 109.24% in 2022 before it plummeted 39.12% in 2023.
- Over 5 years, Accumulated Expenses stood at $16.7 million in 2022, then tumbled by 39.12% to $10.2 million in 2023, then skyrocketed by 95.37% to $19.9 million in 2024, then fell by 4.57% to $18.9 million in 2025, then grew by 1.25% to $19.2 million in 2026.
- Business Quant data shows Accumulated Expenses for SLDB at $19.2 million in Q1 2026, $18.9 million in Q4 2025, and $19.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.18 Mn |
| Dec 31, 2025 | 18.95 Mn |
| Sep 30, 2025 | 19.05 Mn |
| Jun 30, 2025 | 16.55 Mn |
| Mar 31, 2025 | 14.58 Mn |
| Dec 31, 2024 | 19.85 Mn |
| Sep 30, 2024 | 13.23 Mn |
| Jun 30, 2024 | 9.92 Mn |
| Mar 31, 2024 | 10.33 Mn |
| Dec 31, 2023 | 10.16 Mn |
| Sep 30, 2023 | 11.47 Mn |
| Jun 30, 2023 | 10.51 Mn |
| Mar 31, 2023 | 12.38 Mn |
| Dec 31, 2022 | 16.69 Mn |
| Sep 30, 2022 | 10.28 Mn |
| Jun 30, 2022 | 16.14 Mn |
| Mar 31, 2022 | 9.44 Mn |
| Dec 31, 2021 | 9.53 Mn |
| Sep 30, 2021 | 8.00 Mn |
| Jun 30, 2021 | 7.71 Mn |
| Mar 31, 2021 | 6.79 Mn |
| Dec 31, 2020 | 8.64 Mn |
| Sep 30, 2020 | 8.55 Mn |
| Jun 30, 2020 | 8.32 Mn |
| Mar 31, 2020 | 8.51 Mn |
| Dec 31, 2019 | 9.18 Mn |
| Sep 30, 2019 | 11.47 Mn |
| Jun 30, 2019 | 6.01 Mn |
| Mar 31, 2019 | 7.41 Mn |
| Dec 31, 2018 | 8.24 Mn |
| Sep 30, 2018 | 5.83 Mn |
| Jun 30, 2018 | 4.94 Mn |
| Mar 31, 2018 | 4.09 Mn |
| Dec 31, 2017 | 5.97 Mn |